Évaluation de l’efficacité d’un collyre azithromycine 1,5% versus tobramycine 0,3% sur les signes cliniques de la conjonctivite bactérienne purulente

Robert, P.-Y.; Bourcier, Tristan; Meddeb-Ouertani, Amel; Khairallah, Moncef; Zaghloul, K.; Amraoui, A.; Bhagat, Yasmin; Pop, Mihai; Cochereau, Isabelle

doi:10.1016/j.jfo.2010.01.005

Cited by 8 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two of the five studies reported the clinical cure rate of azithromycin ophthalmic solutions is more effective than tobramycin eye drop. 5 , 6 , 11 , 14 In another way, the rest three studies were reported that there was no significant difference in efficacy. 6 , 11 This meta-analysis was based on the duration of treatment, which indicated that azithromycin 1% and 1.5% eye drops provide a more rapid clinical cure than tobramycin 0.3% eye drops in a twice-a-day dosing regimen for short duration (⩽5 days) use (RR = 1.13; 95% CI: 1.008, 1.28).…”

Section: Resultsmentioning

confidence: 94%

“…Similarly, many studies clearly show azithromycin 1.5% for 3 days (six drops) was as effective and safe as tobramycin for 7 days (36 drops). 11 , 13 , 14 The azithromycin 1.5% regimen produced a rapid resolution of cardinal signs of purulent bacterial conjunctivitis with a more convenient dosage regimen. Such improved convenience is likely to improve compliance and lessen the burden of illness for patients and carers.…”

Section: Discussionmentioning

confidence: 99%

“… 6 , 11 , 12 Azithromycin 1% is safe and can be administered in a regimen of less frequent doses than can tobramycin. 14 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of azithromycin 1% and 1.5% ophthalmic solutions compared to tobramycin 0.3% eye drops: A systematic review and meta-analysis

Motbaynor

Worku

2020

SAGE Open Medicine

View full text Add to dashboard Cite

Background: Azithromycin 1% and 1.5% ophthalmic preparations are used widely in clinical practice for the treatment of signs and symptoms of eye diseases. The aim of this study was to render conclusive evidence by comparing the efficacy of azithromycin 1% and 1.5% over tobramycin 0.3% ophthalmic solutions for the treatment of eye diseases in a short duration in terms of bacterial resolution, the cure rate, and resolving clinical sign and symptoms. Methods: Systematic searches were performed in the electronic database (MEDLINE, Embase, Emcare, CINAHL, Scopus, PubMed, ProQuest, and Web of Science) and other sources. Multicenter randomized controlled trial studies conducted in English were identified and screened. Analysis of individual studies was conducted using the OpenMeta-analyst and Review Manager Version 5.3 software. Results: Eleven studies were included in the systematic review and meta-analysis. In clinical cure rate, azithromycin 1% and 1.5% eye drops were more effective than tobramycin 0.3% eye drops in short duration dosing (⩽5 days) with a twice-a-day regimen (relative risk = 1.13; 95% confidence interval: 1.008, 1.28), whereas on increased duration (>5 days), azithromycin is almost similarly as effective as tobramycin (relative risk = 1.007; 95% confidence interval: 0.96, 1.05). There was no significant difference in efficacy of bacterial resolution of azithromycin (1%, 1.5%) eye drops compared to tobramycin (0.3%) eye drops (relative risk = 0.99; 95% confidence interval: 0.96, 1.018). Azithromycin eye drops are effective in improving the signs and symptoms of eye disease. Conclusion: Azithromycin 1% or 1.5% is more effective in the clinical cure rate of eye disease than tobramycin 0.3% eye drops in ⩽5 days of treatment. It is also the best choice of treatment for improving the signs and symptoms of eye disease. So that we recommend clinicians to use azithromycin 1% or 1.5% eye drops. Systematic Review Registration: PROSPERO 2019 CRD42019139911

show abstract